

Amendments in the Claims:


1. (Canceled)
2. (Cancel)
3. (Canceled)
4. (Canceled)
5. (Canceled)
6. (Canceled)
7. (Canceled)
8. (Canceled)
9. (Canceled)
10. (Canceled)
11. (Canceled)
12. (Cancel)
13. (Cancel)
14. (Cancel)
15. (Cancel)

16. (Cancel)

17. (Cancel)

18. (Cancel)

19. (Previously Presented) A compound having the formula:



wherein:

X is CH;

Y is oxygen;

Z is oxygen;

R is CO₂H;

R² is methyl;

R³ is methyl;

R⁴ is phenyl;

R⁵ is phenyl; and

R⁶ is methyl,

or a pharmaceutically acceptable salt thereof.

20. (Currently Amended) The compound of ~~formula I as defined in~~ claim 19, wherein [the] said compound is [further defined as] an optically active enantiomer.


21. (Currently Amended) The compound of claim 20, wherein the enantiomer is the S enantiomer [, and salts thereof].

22. (Currently Amended) The compound of claim [20] 21, wherein the enantiomer is the pure form of the S enantiomer.

23. (Currently Amended) The compound of claim 20, wherein the enantiomer is the R enantiomer [, and salts thereof].

24. (Currently Amended) The compound of claim [20] 23, wherein the enantiomer is the pure form of the R enantiomer.

25. (Currently Amended) A pharmaceutical [formulation] composition comprising a compound having the formula:



wherein:

X is CH;

Y is oxygen;

Z is oxygen;

R is CO₂H;

R² is methyl;

R³ is methyl;

R⁴ is phenyl;

R⁵ is phenyl;

R⁶ is methyl; or a


pharmaceutically acceptable salt thereof,

~~dispersed in a pharmaceutical buffer, diluent or excipient~~ and a pharmaceutically acceptable carrier.

26. (Currently Amended) The [formulation] composition of claim 25, ~~formulated for delivery via wherein said composition is suitable for oral, parenteral, subcutaneous, intravenous, intramuscular, intraperitoneal, sublingual, transdermal or nasopharyngeal [routes] delivery.~~
27. (Currently Amended) The [formulation] composition of claim 25, wherein the [compound] composition is in a solid form.
28. (Currently Amended) The [formulation] composition of claim 25, wherein the [compound] composition is in a liquid form.
29. (Currently Amended) The [formulation] composition of claim 25, wherein the [compound] composition is in the form of a ~~formulated as an uncoated tablet, as a coated tablet,~~ [a] capsule, [a] powder, [a] granule, [a] suppository, [a] solution, [a] colloid, [an] ointment, [a] cream, [a] vapor or [a] spray.
30. (Currently Amended) The [formulation] composition of claim 25, ~~further comprising one or more of~~ wherein the carrier comprises a tablet binder, [a] filler, [a] preservative, [a] tablet disintegrant, [a] flow regulator, [a] plasticizer, [a] wetting agent, [a] dispersant, [an] emulsifier, [a] solvent, [a] release-slowing agent, [an] antioxidant, or [a] propellant gas.
31. (Currently Amended) The [formulation] composition of claim 25, wherein the compound is an optically active enantiomer.
32. (Currently Amended) The [formulation] composition of claim 31, wherein the enantiomer is the S enantiomer [, and salts thereof].
33. (Currently Amended) The [formulation] composition of claim [31] 32, wherein the enantiomer is the pure form of the S enantiomer.
34. (Currently Amended) The [formulation] composition of claim 31, wherein the enantiomer is the R enantiomer [, and salts thereof].

35. (Currently Amended) The [formulation] composition of claim [31] 34, wherein the enantiomer is the pure form of the R enantiomer.

36. (Previously Presented) A compound of the formula:



wherein:

X is CH;

Y is oxygen;

Z is oxygen;

R is CO₂H;

R² is methoxy;

R³ is methoxy;

R⁴ is phenyl;

R⁵ is phenyl;

R⁶ is methyl,

or a pharmaceutically acceptable salt thereof.

37. (Currently Amended) The compound of claim 36, wherein [the] said compound is an optically active enantiomer.


38. (Currently Amended) The compound of claim 37, wherein the enantiomer is the S enantiomer [, and salts thereof].

39. (Currently Amended) The compound of claim [37] 38, wherein the enantiomer is the pure form of the S enantiomer.

40. (Currently Amended) The compound of claim 37, wherein the enantiomer is the R enantiomer [, and salts thereof].

41. (Currently Amended) The compound of claim [37] 40, wherein the enantiomer is the pure form of the R enantiomer.

42. (Currently Amended) A pharmaceutical [formulation] composition comprising a compound having the formula:



wherein:

X is CH;

Y is oxygen;

Z is oxygen;

R is CO₂H;

R² is methoxy;

R³ is methoxy;

R⁴ is phenyl;

R⁵ is phenyl;

R⁶ is methyl; or a

pharmaceutically acceptable salt thereof,

~~dispersed in a pharmaceutical buffer, diluent or excipient~~ and a pharmaceutically acceptable carrier.

43. (Currently Amended) The [formulation] composition of claim 42, ~~formulated for delivery via wherein said composition is suitable for oral, parenteral, subcutaneous, intravenous, intramuscular, intraperitoneal, sublingual, transdermal or nasopharyngeal [routes] delivery.~~

44. (Currently Amended) The [formulation] composition of claim 42, wherein the [compound] composition is in a solid form.

45. (Currently Amended) The [formulation] composition of claim 42, wherein the [compound] composition is in a liquid form.

46. (Currently Amended) The [formulation] composition of claim 42, wherein the [compound] composition is in the form of a ~~formulated as an uncoated tablet, as a coated tablet,~~ [a] capsule, [a] powder, [a] granule, [a] suppository, [a] solution, [a] colloid, [an] ointment, [a] cream, [a] vapor or [a] spray.

47. (Currently Amended) The [formulation] composition of claim 42, ~~further comprising one or more of~~ wherein the carrier comprises a tablet binder, [a] filler, [a] preservative, [a] tablet disintegrant, [a] flow regulator, [a] plasticizer, [a] wetting agent, [a] dispersant, [an] emulsifier, [a] solvent, [a] release-slowing agent, [an] antioxidant, or [a] propellant gas.

48. (Currently Amended) The [formulation] composition of claim 42, wherein the compound is an optically active enantiomer.

49. (Currently Amended) The [formulation] composition of claim 48, wherein the enantiomer is the S enantiomer [, and salts thereof].

50. (Currently Amended) The [formulation] composition of claim [48] 49, wherein the enantiomer is the pure form of the S enantiomer.

51. (Currently Amended) The [formulation] composition of claim 48, wherein the enantiomer is the R enantiomer [, and salts thereof].

52. (Currently Amended) The [formulation] composition of claim [48] 51, wherein the enantiomer is the pure form of the R enantiomer.